Upon completion of this learning program, you will be able to::

• Define CLL and identify its 2 disease subtypes.
• Describe the general epidemiology trends and risk factors for CLL.
• Explain the tools used to establish diagnosis and determine prognosis for CLL.
• Discuss the clinical management of CLL.

1. WELCOME
   1. Disclaimer
   2. Navigation Instructions
   3. Introduction
   4. Learning Objectives
2. PATHOLOGY AND CLASSIFICATION OF CLL
   1. Lymphomas
      • Hand icon: Hodgkin lymphoma
      • Hand icon: Non-Hodgkin lymphoma
   2. Chronic Lymphocytic Leukemia
      • Side note: Digging deeper
   3. Cellular Origins of CLL
      • Popup: Somatic hypermutation
      • Animated popup: CLL disease mechanism (Narrated)
   4. CLL Disease Subtypes
      • Hand icon: IgV-unmutated CLL
      • Hand icon: IgV-mutated CLL
   5. Pop Quiz
   6. Molecular Genetics of CLL
   7. Common Chromosomal Abnormalities in CLL
      • Popup: 13q deletion
      • Popup: 11q deletion
      • Popup: 17p deletion
      • Popup: Additional chromosome
3. CASE STUDY
4. EPIDEMIOLOGY
   1. Incidence of CLL
      • Popup: Age, gender, and race
      • Popup: Family history and genetic predisposition
   2. Progress Check
5. CASE STUDY
6. DIAGNOSIS AND PROGNOSIS OF CLL
   1. Overview
   2. Clinical Presentation and Differential Diagnosis
      • Popup: Clinical manifestation of other diseases
      • Side note: Digging deeper
   3. Peripheral Blood Tests
      • Popup: CLL cells under the microscope
   4. Pop Quiz
   5. Immunophenotyping and Flow Cytometry
      • Popup: Differential diagnosis with flow cytometry
   6. Fluorescence in situ Hybridization
   7. Bone Marrow Aspiration and Biopsy
      • Hand Icon: Bone marrow aspiration
      • Hand Icon: Bone marrow biopsy
   8. Staging
      • Popup: Rai system
      • Popup: Binet system
   9. Pop Quiz
   10. Prognostic Markers
       • Popup: IgV mutational status
       • Popup: CD38 immunophenotype
       • Popup: ZAP-70 expression
       • Popup: Chromosomal abnormalities
       • Popup: Levels of serum β-2 microglobulin and lymphocyte doubling time
   11. Clinical Complications
       • Hand Icon: Risk of infection
       • Hand Icon: Autoimmunity
       • Hand Icon: Transformation
       • Hand Icon: Secondary malignancies
   12. Progress Check
7. CASE STUDY
8. CLINICAL MANAGEMENT OF CLL
   1. Case Study and Overview
   2. Treatment Initiation
   3. Chemotherapy
      • Popup: Alkylating agents
      • Popup: Purine nucleoside analogs
      • Popup: Bifunctional agents
   4. Pop Quiz
   5. Immunotherapy
   6. Combination Therapies
      • Popup: Fludarabine, cyclophosphamide, and rituximab
      • Popup: Fludarabine and rituximab
      • Popup: Pentostatin, cyclophosphamide, and rituximab
      • Popup: Bendamustine and rituximab
   7. Supportive Care
   8. Pop Quiz
   9. Recurrent Disease
      • Popup: Relapsed and refractory patients
      • Popup: Additional cytogenetic abnormalities
   10. Progress Check
9. TEST YOUR ACQUIRED KNOWLEDGE
   1. Summary
   2. Final Assessment
10. END OF PROGRAM
11. GLOSSARY
12. REFERENCES